Cargando…
Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy
Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy by restoring the host antitumor immune response. Since 2011, various ICIs have been approved for the treatment of cancers, which has led to unprecedented prolongation of the survival time for some patients. Although ICIs ha...
Autores principales: | Liu, Weiwei, Liu, Chaoqun, Wang, Hui, Xu, Lijun, Zhou, Jueyu, Li, Sihua, Cheng, Yu, Zhou, Rui, Zhao, Liang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Research Network of Computational and Structural Biotechnology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508382/ https://www.ncbi.nlm.nih.gov/pubmed/36187919 http://dx.doi.org/10.1016/j.csbj.2022.09.017 |
Ejemplares similares
-
Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy
por: Zhou, Xianyong, et al.
Publicado: (2023) -
RNA N(6)-Methyladenosine Modifications and the Immune Response
por: Wang, Ya-Nan, et al.
Publicado: (2020) -
The importance of N6-methyladenosine modification in tumor immunity and immunotherapy
por: Zhang, Ze, et al.
Publicado: (2022) -
N(6)-methyladenosine (m(6)A) RNA modification in tumor immunity
por: Zheng, Siyi, et al.
Publicado: (2022) -
N6-Methyladenosine RNA Modification in the Tumor Immune Microenvironment: Novel Implications for Immunotherapy
por: Guo, Liting, et al.
Publicado: (2021)